BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 7688961)

  • 1. A receptor mediated delivery of an HIV-1 derived peptide vaccine.
    Mitsuda S; Nakagawa T; Osada T; Shimamoto T; Nakazato H; Ikai A
    Biochem Biophys Res Commun; 1993 Aug; 194(3):1155-60. PubMed ID: 7688961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A receptor-mediated antigen delivery and incorporation system. Administration of alpha 2-macroglobulin-cytochrome c conjugate induced high concentrations of antibodies against cytochrome c in mice.
    Mitsuda S; Nakagawa T; Osada T; Ikai A
    Biochem Biophys Res Commun; 1993 Mar; 191(3):1326-31. PubMed ID: 7682069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection.
    Okuda K; Kaneko T; Yamakawa T; Tanaka S; Shigematsu T; Yamamoto A; Hamajima K; Nakajima K; Kawamoto S; Phanuphak P
    J Mol Recognit; 1993 Sep; 6(3):101-9. PubMed ID: 8060667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong synergistic effects of multicomponent vaccine for human immunodeficiency virus infection.
    Okuda K; Kaneko T; Yamakawa T; Tanaka S; Hamajima K; Shigematsu T; Yamamato A; Kawamoto S
    J Clin Lab Immunol; 1993; 40(3):97-113. PubMed ID: 7877154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broader cross-reactivity after conjugation of V3 based multiple antigen peptides to HBsAg.
    Iglesias E; Aguilar JC; Cruz LJ; Reyes O
    Mol Immunol; 2005 Jan; 42(1):99-104. PubMed ID: 15488948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1.
    Cruz LJ; Iglesias E; Aguilar JC; Cabrales A; Reyes O; Andreu D
    Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R; Meyer D
    Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype.
    McNicholl JM; Bond KB; Ruhadze ER; Olsen MR; Takayama K; Hunter RL
    AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1457-71. PubMed ID: 9824324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor-linked antigen delivery system. Importance of autologous alpha 2-macroglobulin in the development of peptide vaccine.
    Mitsuda S; Nakagawa T; Nakazato H; Ikai A
    Biochem Biophys Res Commun; 1995 Nov; 216(1):399-405. PubMed ID: 7488118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
    Fiorentini S; Marini E; Bozzo L; Trainini L; Saadoune L; Avolio M; Pontillo A; Bonfanti C; Sarmientos P; Caruso A
    Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to viral infection by intraepithelial lymphocytes in HIV-1 P18-I10-specific T-cell receptor transgenic mice.
    Kuribayashi H; Wakabayashi A; Shimizu M; Kaneko H; Norose Y; Nakagawa Y; Wang J; Kumagai Y; Margulies DH; Takahashi H
    Biochem Biophys Res Commun; 2004 Apr; 316(2):356-63. PubMed ID: 15020225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.
    Porgador A; Staats HF; Faiola B; Gilboa E; Palker TJ
    J Immunol; 1997 Jan; 158(2):834-41. PubMed ID: 8993001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA.
    Moss RB; Diveley J; Jensen FC; Gouveia E; Carlo DJ
    J Hum Virol; 2001; 4(1):39-43. PubMed ID: 11213932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
    Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
    Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.